TABLE 7

Impact of PET on Intended Management for Detection of Suspected Recurrence by Cancer Type^*

Cancer type	No. of scans	% of cases with change in management^†	95% CI	Imaging-adjusted impact (%)^‡	95% CI
Ovary	2,160	44.5	42.4–46.6	19.1	17.4–20.7
Prostate	1,790	39.4	37.2–41.7	18.0	16.3–19.8
Uterus	1,059	38.8	35.9–41.7	19.3	16.9–21.6
Kidney	1,003	32.4	29.5–35.3	18.2	15.9–20.6
Bladder	878	36.7	33.5–39.9	19.8	17.2–22.5
Pancreas	802	39.3	35.9–42.7	22.1	19.2–24.9
Stomach	553	29.3	25.5–33.1	15.2	12.2–18.2
Small cell lung	544	38.1	34.0–42.1	20.2	16.8–23.6
Myeloma	373	50.9	45.9–56.0	14.7	11.1–18.3
Connective tissue	366	34.7	29.8–39.6	15.8	12.1–19.6
Cervix	290	35.9	30.3–41.4	16.9	12.6–21.2
Thyroid	253	33.2	27.4–39.0	17.0	12.4–21.6
Primary brain	222	40.5	34.1–47.0	28.4	22.4–34.3
Other female genital	206	39.8	33.1–46.5	17.5	12.3–22.7
All other	1,415	35.1	32.6–37.5	19.4	17.3–21.4
Total	11,914	38.5	37.6–39.3	18.8	18.1–19.5

↵* Specific cancer types are listed when there were at least 200 cases.
↵† Defined as change from treatment to nontreatment or as change from nontreatment to treatment.
↵‡ No benefit from PET was assumed for cases with imaging plan before PET.